Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $104000.0.

  • Guided Therapeutics' Non-Current Assets fell 4951.46% to $104000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $104000.0, marking a year-over-year decrease of 4951.46%. This contributed to the annual value of $181000.0 for FY2024, which is 3442.03% down from last year.
  • Guided Therapeutics' Non-Current Assets amounted to $104000.0 in Q3 2025, which was down 4951.46% from $129000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Non-Current Assets registered a high of $446000.0 during Q1 2021, and its lowest value of $104000.0 during Q3 2025.
  • For the 5-year period, Guided Therapeutics' Non-Current Assets averaged around $301578.9, with its median value being $319000.0 (2023).
  • In the last 5 years, Guided Therapeutics' Non-Current Assets surged by 57096.77% in 2021 and then crashed by 4951.46% in 2025.
  • Quarter analysis of 5 years shows Guided Therapeutics' Non-Current Assets stood at $403000.0 in 2021, then fell by 10.17% to $362000.0 in 2022, then fell by 23.76% to $276000.0 in 2023, then crashed by 34.42% to $181000.0 in 2024, then crashed by 42.54% to $104000.0 in 2025.
  • Its last three reported values are $104000.0 in Q3 2025, $129000.0 for Q2 2025, and $156000.0 during Q1 2025.